These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 29426782)

  • 21. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
    Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
    World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
    Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A
    Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Howell SJ; Wardley AM; Armstrong AC
    J Natl Cancer Inst; 2009 Dec; 101(24):1730; author reply 1730-1. PubMed ID: 19893007
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
    Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
    PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
    Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
    Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer.
    Brennan M; Lim B
    Adv Exp Med Biol; 2015; 867():327-37. PubMed ID: 26530375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
    Chapman JA; Sgroi DC; Goss PE; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Badovinac-Crnjevic T; Shepherd LE; Pollak MN
    Breast Cancer Res Treat; 2016 May; 157(1):101-8. PubMed ID: 27116182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women.
    Crispo A; Montella M; Buono G; Grimaldi M; D'Aiuto M; Capasso I; Esposito E; Amore A; Nocerino F; Augustin LS; Giudice A; Di Bonito M; Giuliano M; Forestieri V; De Laurentiis M; Rinaldo M; Ciliberto G; De Placido S; Arpino G
    Curr Res Transl Med; 2016; 64(1):15-20. PubMed ID: 27140595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discordance and Conversion Rates of Progesterone-, Estrogen-, and HER2/neu-Receptor Status in Primary Breast Cancer and Brain Metastasis Mainly Triggered by Hormone Therapy.
    Timmer M; Werner JM; Röhn G; Ortmann M; Blau T; Cramer C; Stavrinou P; Krischek B; Mallman P; Goldbrunner R
    Anticancer Res; 2017 Sep; 37(9):4859-4865. PubMed ID: 28870906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
    Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes of expression of estrogen and progestrone receptors, human epithelial growth factor receptor 2 and Ki-67 after neoadjuvant chemotherapy in the treatment of breast cancer.
    Li ML; Dong Y; Luan SL; Zhao ZH; Ning FL
    J Biol Regul Homeost Agents; 2016; 30(4):1059-1065. PubMed ID: 28078854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
    Xian Z; Quinones AK; Tozbikian G; Zynger DL
    Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2 status in elderly women with breast cancer.
    Laird-Fick HS; Gardiner JC; Tokala H; Patel P; Wei S; Dimitrov NV
    J Geriatr Oncol; 2013 Oct; 4(4):362-7. PubMed ID: 24472480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Night work and breast cancer risk defined by human epidermal growth factor receptor-2 (HER2) and hormone receptor status: A population-based case-control study in France.
    Cordina-Duverger E; Koudou Y; Truong T; Arveux P; Kerbrat P; Menegaux F; Guénel P
    Chronobiol Int; 2016; 33(6):783-7. PubMed ID: 27078711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analytical and clinical performance of progesterone receptor antibodies in breast cancer.
    Calhoun BC; Mosteller B; Warren D; Smith M; Jordi Rowe J; Lanigan CP; Mrazeck KC; Walker E; Newell AH; Jones R
    Ann Diagn Pathol; 2018 Aug; 35():21-26. PubMed ID: 29758480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.